In Alzheimer's, More ZZZs Once Wakefulness Neurons Die
In people who had Alzheimer’s disease, degeneration of subcortical neurons that drive wakefulness correlated with more time asleep at night.
ALL NEWS
6066 RESULTS
Sort By:
- Most Recent
- Most Commented
Is This Mutation Pathogenic? Alzforum Updates System for Making This Call
Applied to more than 500 alleles in APP, PSEN1, and PSEN2, the new classification can help scientists gauge how pathogenic, or benign, a given variant might be
DNA Nuclease Fans the Flames of Huntington’s Disease
Rare genetic variants that blunt FAN1 activity cause rapid expansion of CAG trinucleotide repeats in somatic cells.
Surprise! TMEM106b Fibrils Found in Neurodegenerative Diseases
In a game changer for the field, three papers report similar structures for TMEM106b fibrils. One claims they comprise the lion’s share of TDP-43 aggregates.
UB-312 Synuclein Vaccine Safe in Controls. Next Up: Parkinson's.
In the field's quest for disease-modifying treatments, two different α-synuclein vaccines and two antibodies look promising in preclinical studies, as well.
Eavesdropping on Cell-to-Cell Conversations in Aging, Alzheimer's
New, unbiased single-cell methods uncover coordinated changes in cell populations and their interactions. These correlate with disease pathology, progression.
Does Norepinephrine Metabolite DOPEGAL Turn Tau Toxic?
DOPEGAL is produced in the locus coeruleus, the initial site of tau aggregation. In tauopathy mice, suppressing DOPEGAL prevented the spread of pathological tau.
Paper Alert: Massive GWAS Meta-Analysis Published
The huge collaborative effort unearthed 42 new risk loci and confirmed 33 others. The hits reinforce known disease pathways and predict progression.
Just Like Viruses, Tau Can Unleash Interferons
By triggering release of mitochondrial DNA, tau fibrils may set off a cytosolic sensor that activates the interferon response. Blocking this sensor spared neurons and memory in mice.
Scientists Re-Analyze Aduhelm Data, Try to Parse Who Benefits
At AD/PD, some speakers sought to bolster the argument that amyloid removal slows cognitive decline, while others identified what type of patient is most likely to benefit.
Using Lecanemab Trial Data to Determine Maintenance Dose
At AD/PD, researchers presented pharmacologic analyses that could help predict antibody effects and select the right dosage to keep plaques at bay.
In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy
A new tracer detects α-synuclein aggregates in people with multiple system atrophy. Binding is weak, and undetectable in people with other synucleinopathies.
TAPAS Anyone? PyroGlu-Aβ Vaccine Shrinks Plaques in Mice
The new vaccine stalled neurodegeneration and improved learning. An antibody that binds the same epitope had similar effects, and only binds soluble oligomers.
AD/PD 2022: Advances in Science and Therapy (Hybrid Virtual and In-Person)
Gantenerumab Prevention Trial in Sporadic Alzheimer's Begins In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy Using Lecanemab Trial Data to Determine Maintenance Dose Scientists Re-Analyze Aduhelm Data, Try to Parse Who Benef
Gantenerumab Prevention Trial in Sporadic Alzheimer's Begins
Taking a stab at secondary prevention, the four-year Phase 3 trial will assess the antibody’s ability to slow slippage in 1,200 cognitively healthy, amyloid-positive people.
Current Filters
No filters selected